Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.
作者： Helce Haarstad , Stein Gundersen , Erik Wist , Nils Raabe , Olav Mella
DOI: 10.3109/02841869209088284
关键词: Tamoxifen 、 Oncology 、 Phases of clinical research 、 Adjuvant 、 Cancer 、 Mammary gland 、 Chemotherapy 、 Oral administration 、 Antiestrogen 、 Internal medicine 、 Surgery 、 Medicine
摘要: Twenty-six patients with advanced breast cancer were treated a new anti-estrogen, Droloxifene (3-hydroxy-tamoxifen). They had all used tamoxifen either in the adjuvant or situation. The dose schedule was 100 mg orally daily. Partial remissions observed 4 (15%) of patients, and another 5 stable disease (> 24 weeks duration) observed. Three responders resistant to tamoxifen. Fourteen 26 no side-effect. In 2 therapy be stopped due fatigue. seems an interesting anti-estrogen which should further exploited.
sci-hub.se 参考文章(17)
Micaela M.-T. Buckley, Karen L. Goa, Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. ,vol. 37, pp. 451- 490 ,(1989) , 10.2165/00003495-198937040-00004
Manfred Dietel, Roland L�ser, Peter R�hlke, Walter Jonat, Axel Niendorf, Daisy Gerding, Angelika Kohr, Fritz H�lzel, Hartmut Arps, Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1 Journal of Cancer Research and Clinical Oncology. ,vol. 115, pp. 36- 40 ,(1989) , 10.1007/BF00391597
G. Bertelli, P. Pronzato, D. Amoroso, M. P. Cusimano, P. F. Conte, G. Montagna, S. Bertolini, R. Rosso, Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Research and Treatment. ,vol. 12, pp. 307- 310 ,(1988) , 10.1007/BF01811244
Stener Kvinnsland, Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients. American Journal of Clinical Oncology. ,vol. 14, pp. 46- 51 ,(1991) , 10.1097/00000421-199112002-00010
J. L. Hayward, P. P. Carbone, J-C Heuson, S. Kumaoka, A. Segaloff, R. D. Rubens, Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland Cancer. ,vol. 39, pp. 1289- 1294 ,(1977) , 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F
H. J. Grill, K. Pollow, Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients American Journal of Clinical Oncology. ,vol. 14, pp. 21- 29 ,(1991) , 10.1097/00000421-199112002-00006
Stephan Rössner, Arne Wallgren, Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis. ,vol. 52, pp. 339- 346 ,(1984) , 10.1016/0021-9150(84)90064-9
S. Turken, E. Siris, D. Seldin, E. Flaster, G. Hyman, R. Lindsay, Effects of tamoxifen on spinal bone density in women with breast cancer Journal of the National Cancer Institute. ,vol. 81, pp. 1086- 1088 ,(1989) , 10.1093/JNCI/81.14.1086
S. Kvinnsland, How to improve endocrine therapy of breast cancer. Acta Oncologica. ,vol. 29, pp. 387- 389 ,(1990) , 10.3109/02841869009090019
Tommy Fornander, Björn Cedermark, Anders Mattsson, Lambert Skoog, Tolle Theve, Jutta Askergren, LabsE. Rutqvist, Ulla Glas, Claes Silfverswärd, Anders Somell, Nils Wilking, Marie-Louise Hjalmar, ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS The Lancet. ,vol. 333, pp. 117- 120 ,(1989) , 10.1016/S0140-6736(89)91141-0